ProCE Banner Activity

Key Updates in the Treatment of HER2-Positive Breast Cancer

Slideset Download
Download this slideset from Jeremy Force, DO, MA; Nicholas McAndrew, MD, MSCE, and Sara M. Tolaney, MD, MPH with the most recent data for managing patients with HER2-positive advanced breast cancer.

Released: May 11, 2020

Expiration: May 10, 2021

No longer available for credit.

Share

Faculty

Jeremy Force

Jeremy Force, DO

Assistant Professor
Breast Oncology Program
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

Nicholas P. McAndrew

Nicholas P. McAndrew, MD, MSCE

Health Sciences Clinical Instructor
Division of Hematology/Oncology
Department of Medicine
UCLA David Geffen School of Medicine
Los Angeles, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Seagen

Faculty Disclosure

Primary Author

Jeremy Force, DO

Assistant Professor
Breast Oncology Program
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

Nicholas P. McAndrew, MD, MSCE

Health Sciences Clinical Instructor
Division of Hematology/Oncology
Department of Medicine
UCLA David Geffen School of Medicine
Los Angeles, California

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts